share_log

RBC Capital Initiates Coverage On Fulcrum Therapeutics With Outperform Rating, Announces Price Target of $14

Moomoo 24/7 ·  Mar 13 12:31

RBC Capital analyst Gregory Renza initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Outperform rating and announces Price Target of $14.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment